



# CONTENTS

	<i>Page</i>
<b>DEFINITIONS</b> .....	1
<b>LETTER FROM THE BOARD</b> .....	3
1. ....	4
2. <b>Amendment to Article 1</b> .....	4
2022 <b>W</b> .....	4
2022 <b>W</b> .....	5
2022 <b>A</b> .....	5
2022 <b>H</b> .....	5
2022 <b>A</b> .....	5
2022 <b>A</b> .....	5
2022 <b>A</b> .....	6
2022 <b>A</b> .....	6
2022 <b>A</b> .....	7
2022 <b>A</b> .....	7
2022 <b>A</b> .....	9
2023 <b>A</b> .....	9
2023 <b>A</b> .....	9
3. <b>Amendment to Article 2</b> .....	9
4. ....	10
5. ....	11
<b>APPENDIX I – PROFILES OF THE PROPOSED SIXTH SESSION OF THE BOARD</b> ...	12
<b>APPENDIX II – AMENDMENT OF ARTICLES OF ASSOCIATION</b> .....	18
<b>NOTICE OF THE 2022 ANNUAL GENERAL MEETING</b> .....	20

*Note:* ...

---

## DEFINITIONS

---

*In this circular, unless the context otherwise requires, the following terms shall have the following meanings:*

7 A 



---

LETTER FROM THE BOARD

---



**SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.**  
( 深圳市海普瑞藥業集團股份有限公司 )  
(A joint stock company incorporated in the People's Republic of China with limited liability)  
(Stock code: 9989)

*Executive Directors:*

★ · · · · · (Chairman of the Board)  
★ · · · · · (Deputy General Manager)  
★ · 2 · · · · · (General Manager)

*Independent non-executive Directors:*

★ · · · · ·  
★ W · · · · · Z · · · · ·

*Registered office in the PRC:*

· · · · · 21 · · · · ·  
2 · · · · ·  
§ · · · · ·

*Principal place of business  
in Hong Kong:*

4724, 471-  
2 · · · · · H · · · · ·  
30 H · · · · ·  
W · · · · · H · · · · ·

A · · · · · 20, 2023

*To the Shareholders*

2 · · · · · ★ · · · · ·

**2022 WORK REPORT OF THE BOARD OF DIRECTORS  
2022 WORK REPORT OF THE SUPERVISORY COMMITTEE  
2022 ANNUAL REPORT AND ITS SUMMARY,  
H SHARES RESULTS ANNOUNCEMENT,  
H SHARES 2022 ANNUAL REPORT,  
2022 CORPORATE GOVERNANCE REPORT AND  
2022 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT  
2022 FINAL FINANCIAL REPORT  
2022 PROFIT DISTRIBUTION PROPOSAL  
RE-APPOINTMENT OF AUDITORS OF THE COMPANY  
ELECTION OF THE SIXTH SESSION OF THE BOARD  
REMUNERATION OF INDEPENDENT NON-EXECUTIVE DIRECTORS OF  
THE SIXTH SESSION OF THE BOARD  
ELECTION OF THE SIXTH SESSION OF THE SUPERVISORY COMMITTEE  
PURCHASE OF WEALTH MANAGEMENT PRODUCTS AND  
CASH FLOW MANAGEMENT  
USING INTERNAL FUNDS  
APPLICATION FOR CREDIT LINE AND PROVIDING GUARANTEE TO  
CERTAIN BANKS FOR 2023  
AMENDMENT OF ARTICLES OF ASSOCIATION**

---

# LETTER FROM THE BOARD

---

## 1. INTRODUCTION

The Board of Directors (the "Board") of the Company (the "Company") is pleased to announce that the Annual Meeting of the Shareholders (the "Annual Meeting") will be held on Wednesday, May 24, 2023, at 10:00 a.m. (local time) at the Company's headquarters, located at [Address], [City], [Country].

The Board has decided to hold the Annual Meeting in a hybrid format, allowing shareholders to attend in person or virtually.

- (1) The Board has approved the 2022 Work Report of the Board of Directors.
- (2) The Board has approved the 2022 Work Report of the Management.
- (3) The Board has approved the 2022 Annual Report, the 2022 Financial Statements, the 2022 Dividend Policy, and the 2023 Business Plan.
- (4) The Board has approved the 2022 Environmental, Social, and Governance Report.
- (5) The Board has approved the 2022 Sustainability Report.
- (6) The Board has approved the 2022 Human Resources Report.
- (7) The Board has approved the 2022 Risk Management Report.
- (8) The Board has approved the 2022 Internal Control Report.
- (9) The Board has approved the 2022 Audit Report.

- (10) The Board has approved the 2022 Corporate Governance Report.
- (11) The Board has approved the 2022 Shareholder Relations Report.
- (12) The Board has approved the 2022 Information Disclosure Report.

The Board has also approved the 2022 Work Report of the Board of Directors, the 2022 Work Report of the Management, the 2022 Annual Report, the 2022 Financial Statements, the 2022 Dividend Policy, and the 2023 Business Plan.

- (10) The Board has approved the 2022 Work Report of the Board of Directors, the 2022 Work Report of the Management, the 2022 Annual Report, the 2022 Financial Statements, the 2022 Dividend Policy, and the 2023 Business Plan.
- (11) The Board has approved the 2022 Environmental, Social, and Governance Report, the 2022 Sustainability Report, the 2022 Human Resources Report, the 2022 Risk Management Report, the 2022 Internal Control Report, and the 2022 Audit Report.
- (12) The Board has approved the 2022 Corporate Governance Report, the 2022 Shareholder Relations Report, and the 2022 Information Disclosure Report.

## 2. MATTERS TO BE CONSIDERED AT THE ANNUAL GENERAL MEETING

### i. 2022 Work Report of the Board of Directors

The Board has reviewed and approved the 2022 Work Report of the Board of Directors, which details the Board's activities and decisions throughout the year. The report is available on the Company's website at [Website Address].

The Board has also reviewed and approved the 2022 Work Report of the Management, the 2022 Annual Report, the 2022 Financial Statements, the 2022 Dividend Policy, and the 2023 Business Plan. These reports are also available on the Company's website at [Website Address].

---

## LETTER FROM THE BOARD

---

**ii. 2022 Work Report of the Supervisory Committee**

The Supervisory Committee has reviewed the 2022 Work Report of the Supervisory Committee, which was approved by the Board of Directors on December 29, 2023.

**iii. 2022 Annual Report and its Summary, H Shares Results Announcement, H Shares 2022 Annual Report, 2022 Corporate Governance Report and 2022 Environmental, Social and Governance Report**

The Board of Directors has reviewed the 2022 Annual Report and its Summary, H Shares Results Announcement, H Shares 2022 Annual Report, 2022 Corporate Governance Report and 2022 Environmental, Social and Governance Report, which were approved by the Board of Directors on December 29, 2023.

**iv. 2022 Final Financial Report**

The Board of Directors has reviewed the 2022 Final Financial Report, which was approved by the Board of Directors on December 29, 2023.

**v. 2022 Profit Distribution Proposal**

The Board of Directors has reviewed the 2022 Profit Distribution Proposal, which was approved by the Board of Directors on December 29, 2023.

The Board of Directors has reviewed the 2022 Profit Distribution Proposal, which was approved by the Board of Directors on December 29, 2023.

---

## LETTER FROM THE BOARD

---

### vi. Re-appointment of auditors of the Company

At a meeting of the Board of Directors held on 29, 2023, the Board has resolved to re-appoint the auditors of the Company for the year ending 2023.

The Board has also resolved to re-appoint the auditors of the Company for the year ending 2023.

### vii. Election of the sixth session of the Board

At a meeting of the Board of Directors held on 29, 2023, the Board has resolved to elect the sixth session of the Board of Directors. The Board has resolved to elect the following members to the Board of Directors: (Mr. Li), (Mr. Shan), (Dr. Lu), (Mr. Zhang), (Mr. Huang), (Mr. Yi), ( )12.7, ( )12.8 ( )12.A



---

## LETTER FROM THE BOARD

---

§ 2

3.4 A 14

H

H

A

A

A

### viii. Remuneration of independent non-executive Directors of the sixth session of the Board

100,000

§ 2

§ 2

A

### ix. Election of the sixth session of the Supervisory Committee

184

§ 2

§ 2

(Ms. Tang)

Z

(Mr. Zheng)

H

§ 2

§ 2

§ 2

A

---

## LETTER FROM THE BOARD

---

... Z, ...  
... Z, Z (鄭澤輝), ... 53, ...  
... 2006. ...  
... 1992 ...  
... 2011.

... H (唐海均), ... 44, ...  
... 2001 ...  
... 2007. ...  
... 2014.

... Z, ...  
... A ...  
... A ...  
... A ...  
... Z ...

... H ...

... Z, ...  
... H ...

... 13.51(2)(c) ... 13.51(2)(d) ...  
... Z, ...

... Z, ...

---

## LETTER FROM THE BOARD

---

x. **Purchase of Wealth Management Products and Cash Flow Management Using Internal Funds**

On August 29, 2023, the Board of Directors of HCA, Inc. (HCA) approved the purchase of wealth management products and cash flow management products using internal funds of HCA. The purchase of these products is expected to be completed by the end of 2023.

xi. **Application for Credit Line and Providing Guarantee to Certain Banks for 2023**

On August 29, 2023, the Board of Directors of HCA approved the application for a credit line and providing guarantee to certain banks for 2023. The credit line and guarantee are expected to be completed by the end of 2023.

xii. **Amendment of Articles of Association**

On August 29, 2023, the Board of Directors of HCA approved the amendment of the Articles of Association of HCA. The amendment is expected to be completed by the end of 2023.

3. **ANNUAL GENERAL MEETING AND CLOSURE OF REGISTER OF MEMBERS OF HCA SHARES**

The Board of Directors of HCA has determined that the annual general meeting of HCA will be held on October 20, 2023, at 10:00 a.m. Eastern Standard Time at the HCA headquarters, 10000 HCA Drive, HCA, Virginia. The Board of Directors of HCA has also determined that the register of members of HCA shares will be closed from October 20, 2023, to October 24, 2023.



---

## LETTER FROM THE BOARD

---

### 5. RECOMMENDATION

§ 2, A

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Li Li  
*Chairman*

A

**Non-independent Directors**

(i) *Mr. Li Li*

(李鋌), 59, H § 2  
28 H § 2  
A § 2  
2012  
1, 21 ( ) / 808 001 -022136 8110 0 0 10 70.

(ii) Ms. Li Tan

(李坦), 58, ... 28 ... A ... 1998. ... 2007; ... (H ... ) ... 2014; ... 2010; ... H ... 2013; ... A ... 2015; ... 2016.

... 1987 ... 2005.

A ... 922,391,179 A ... 73.96% ... A ... 408,041,280 A ... 99.00% ... 1.00% ... 474,029,899 A ... 99.00% ... 1.00% ... 40,320,000 A ...

(iii) Mr. Shan Yu

YU SHAN (單宇), 62, 28, H, 1998, 2000; 2007; 2009; 2009; 2010; 2013; 2014.

1982, 2005. A, 99%, 46,425,600 A, 38.88%, 15,118,035 A, 52,302,892 A, 3.56%.

(iv) Mr. Zhang Ping

ZHANG PING (張平), 58, 1992, 1998, 2021, 2022, H, 2002, 2021, H, 1988, 2002. A, H, A, H, A.





A ... §

(vi) Mr. Huang Peng

Mr. H (黃鵬), 74, 1949, H 2003. H 1995 1985. H 1988, (新時代企業家研究院) H : 601890), W ( : 301180), J ( : 300819) & : 603828). H

A H A H A H A

A ... H §

(vii) Mr. Yi Ming

Mr. Yi (易銘), 46, 1977, H 2002 A H 2014. H (H ) A 2003 H 2012. H Z (A ) A 2013 J 2018. H A A 2018

A H A H A H A


A ... §



Article 14. The Board of Directors shall have the authority to borrow money on behalf of the Association, to execute any mortgage, deed, lease, contract, or other instrument, and to execute any instrument necessary to carry out its duties, and to execute any instrument necessary to carry out its duties, and to execute any instrument necessary to carry out its duties.

Existing Provisions of the Articles of Association	Proposed Amendments to the Articles of Association
<p><b>Article 14.</b> The Board of Directors shall have the authority to borrow money on behalf of the Association, to execute any mortgage, deed, lease, contract, or other instrument, and to execute any instrument necessary to carry out its duties, and to execute any instrument necessary to carry out its duties, and to execute any instrument necessary to carry out its duties.</p>	<p><b>Article 14.</b> The Board of Directors shall have the authority to borrow money on behalf of the Association, to execute any mortgage, deed, lease, contract, or other instrument, and to execute any instrument necessary to carry out its duties, and to execute any instrument necessary to carry out its duties, and to execute any instrument necessary to carry out its duties.</p>
<p><b>Article 97 A</b> § 2. The Board of Directors shall have the authority to borrow money on behalf of the Association, to execute any mortgage, deed, lease, contract, or other instrument, and to execute any instrument necessary to carry out its duties, and to execute any instrument necessary to carry out its duties, and to execute any instrument necessary to carry out its duties.</p> <p><b>A</b> § 2. The Board of Directors shall have the authority to borrow money on behalf of the Association, to execute any mortgage, deed, lease, contract, or other instrument, and to execute any instrument necessary to carry out its duties, and to execute any instrument necessary to carry out its duties, and to execute any instrument necessary to carry out its duties.</p>	<p><b>Article 97 A</b> § 2. The Board of Directors shall have the authority to borrow money on behalf of the Association, to execute any mortgage, deed, lease, contract, or other instrument, and to execute any instrument necessary to carry out its duties, and to execute any instrument necessary to carry out its duties, and to execute any instrument necessary to carry out its duties.</p> <p><b>A</b> § 2. The Board of Directors shall have the authority to borrow money on behalf of the Association, to execute any mortgage, deed, lease, contract, or other instrument, and to execute any instrument necessary to carry out its duties, and to execute any instrument necessary to carry out its duties, and to execute any instrument necessary to carry out its duties.</p>





---

# NOTICE OF THE 2022 ANNUAL GENERAL MEETING

---

## ORDINARY RESOLUTION

THE BOARD OF DIRECTORS OF THE COMPANY HAS RESOLVED TO AMEND THE ARTICLES OF ASSOCIATION OF THE COMPANY AS SET FORTH IN ANNEXURE 'A' TO THIS NOTICE.

8. THE BOARD OF DIRECTORS OF THE COMPANY HAS RESOLVED TO AMEND THE ARTICLES OF ASSOCIATION OF THE COMPANY AS SET FORTH IN ANNEXURE 'B' TO THIS NOTICE;

## SPECIAL RESOLUTION

THE BOARD OF DIRECTORS OF THE COMPANY HAS RESOLVED TO AMEND THE ARTICLES OF ASSOCIATION OF THE COMPANY AS SET FORTH IN ANNEXURE 'C' TO THIS NOTICE:

9. THE BOARD OF DIRECTORS OF THE COMPANY HAS RESOLVED TO AMEND THE ARTICLES OF ASSOCIATION OF THE COMPANY AS SET FORTH IN ANNEXURE 'D' TO THIS NOTICE;

## ORDINARY RESOLUTIONS

THE BOARD OF DIRECTORS OF THE COMPANY HAS RESOLVED TO AMEND THE ARTICLES OF ASSOCIATION OF THE COMPANY AS SET FORTH IN ANNEXURE 'E' TO THIS NOTICE:

10. THE BOARD OF DIRECTORS OF THE COMPANY HAS RESOLVED TO AMEND THE ARTICLES OF ASSOCIATION OF THE COMPANY AS SET FORTH IN ANNEXURE 'F' TO THIS NOTICE;

THE BOARD OF DIRECTORS OF THE COMPANY HAS RESOLVED TO AMEND THE ARTICLES OF ASSOCIATION OF THE COMPANY AS SET FORTH IN ANNEXURE 'G' TO THIS NOTICE:

11. THE BOARD OF DIRECTORS OF THE COMPANY HAS RESOLVED TO AMEND THE ARTICLES OF ASSOCIATION OF THE COMPANY AS SET FORTH IN ANNEXURE 'H' TO THIS NOTICE:

11.01 THE BOARD OF DIRECTORS OF THE COMPANY HAS RESOLVED TO AMEND THE ARTICLES OF ASSOCIATION OF THE COMPANY AS SET FORTH IN ANNEXURE 'I' TO THIS NOTICE;

11.02 THE BOARD OF DIRECTORS OF THE COMPANY HAS RESOLVED TO AMEND THE ARTICLES OF ASSOCIATION OF THE COMPANY AS SET FORTH IN ANNEXURE 'J' TO THIS NOTICE;

11.03 THE BOARD OF DIRECTORS OF THE COMPANY HAS RESOLVED TO AMEND THE ARTICLES OF ASSOCIATION OF THE COMPANY AS SET FORTH IN ANNEXURE 'K' TO THIS NOTICE;

11.04 THE BOARD OF DIRECTORS OF THE COMPANY HAS RESOLVED TO AMEND THE ARTICLES OF ASSOCIATION OF THE COMPANY AS SET FORTH IN ANNEXURE 'L' TO THIS NOTICE;

---

## NOTICE OF THE 2022 ANNUAL GENERAL MEETING

---

12. 2022年12月31日止年度业绩摘要及全年业绩报告全文；
- 12.01 2022年12月31日止年度业绩摘要全文；
- 12.02 2022年12月31日止年度业绩报告全文；
- 12.03 2022年12月31日止年度业绩报告全文；
13. 2022年12月31日止年度业绩摘要及全年业绩报告全文；
- 13.01 2022年12月31日止年度业绩摘要全文；
- 13.02 2022年12月31日止年度业绩报告全文；

**Shenzhen Hepalink Pharmaceutical Group Co., Ltd.**  
**Li Li**  
*Chairman*

2023年1月20日





---

## NOTICE OF THE 2022 ANNUAL GENERAL MEETING

---

(iii) ... § 2- ... A ...

9. ... **H** ...